
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is well-positioned to capitalize on the growing demand for insulin pumps, particularly in the underserved Type 1 diabetes market. The company has a diversified portfolio of technologies, with its newest insulin pump Mobi entering the market soon and its innovative tubeless patch pump Sigi in development. These developments, coupled with Tandem Diabetes Care's strong customer retention, give us confidence in the company's growth potential. Additionally, the shift towards pharmacy channel sales could lead to higher revenue and margins in the long term. Although there are some risks, such as supply chain disruptions and potential competition from GLP-1s, we believe the company's efforts to expand its market reach and focus on sustainability make it a strong investment opportunity.
Bears say
Tandem Diabetes Care is expected to face challenges in expanding its market share, as it operates in a highly competitive environment and faces potential threats from new entrants. The company's heavy reliance on insulin pumps for the majority of its revenue also poses concerns, particularly as GLP-1s, a potential competitor, could pose a significant threat. Additionally, Tandem's transition to a Pay/Go model may negatively impact its near-term revenues, but the long-term benefits of this model should drive growth and profitability. With a lower profit margin than its peers and potential execution risks, we believe a discounted valuation is warranted, and have a $31 price target for the stock.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares